

HIV DRUG RESISTANCE

MEETING REPORT

# WHO HIV DRUG RESISTANCE NETWORK STEERING GROUP MEETING REPORT

JUNE 2021





**HIV DRUG RESISTANCE**

# **WHO HIV DRUG RESISTANCE NETWORK STEERING GROUP MEETING REPORT**

**JUNE 2021**

WHO HIV drug resistance network steering group meeting report, June 2021

ISBN 978-92-4-003854-7 (electronic version)

ISBN 978-92-4-003855-4 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO HIV drug resistance network steering group meeting report, June 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the report of the HIVResNet steering group meeting and does not necessarily represent the decisions or policies of WHO.

Layout by ACW, London

# CONTENTS

Acknowledgements.....	iv
Abbreviations.....	iv
Background.....	v
Session 1: Welcome and introduction of new Steering Group members.....	1
Session 2: Looking back: what was done in 2020.....	3
Session 3: Looking ahead: what is planned for 2021.....	4
Annex 1. Meeting agenda.....	11
Annex 2. List of participants.....	12

# ACKNOWLEDGEMENTS

This report was written by Seth Inzaule (WHO consultant) with contributions from Neil Parkin (Data First Consulting, Inc., WHO consultant), Amalia Giron (WHO consultant) and Michael R. Jordan (WHO consultant). Michael R. Jordan (WHO consultant, Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University) coordinated the development of the report under the overall coordination of Marco Vitoria (Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, WHO). We are extremely grateful for the participation and contribution of the presenters, Steering Group members and the chairs.

## ABBREVIATIONS

<b>3TC</b>	lamivudine
<b>ABC</b>	abacavir
<b>ART</b>	antiretroviral therapy
<b>CADO</b>	Clinical Adult working group for Drug Optimization
<b>DTG</b>	dolutegravir
<b>FTC</b>	emtricitabine
<b>HIVResNet</b>	HIV drug resistance network
<b>NNRTI</b>	non-nucleoside reverse-transcriptase inhibitor
<b>NRTI</b>	nucleoside reverse-transcriptase inhibitor
<b>PADO</b>	Paediatric working group on Drug Optimization
<b>PI</b>	protease inhibitor
<b>PrEP</b>	pre-exposure prophylaxis
<b>TAF</b>	tenofovir alafenamide
<b>TDF</b>	tenofovir disoproxil fumarate
<b>ZDV</b>	zidovudine

# BACKGROUND

The WHO HIV drug resistance network (HIVResNet) is a group composed of international experts, researchers, laboratorians, organizations, partners, stakeholders, and civil society members. HIVResNet has an important advisory role and implementation function in global efforts to prevent, monitor and respond to HIV drug resistance. Established in 2004 by a partnership between WHO and the International AIDS Society, WHO HIVResNet supports the monitoring and prevention of HIV drug resistance, the optimization of HIV drug resistance testing, the monitoring of the quality of antiretroviral therapy (ART) delivery for preventing HIV drug resistance and the development of policies related to optimal first- and second-line ART.

Governance of WHO HIVResNet is provided by its Steering Group, which also serves as the main advisory body to WHO on HIV drug resistance. The Steering Group advises WHO on strategies to tackle HIV drug resistance that are consistent with WHO's mandate; in addition, Steering Group members chair thematic working groups of the Global Action Plan on HIV drug resistance and support WHO in implementing and reporting on elements of the Global Action Plan. In addition, Steering Group members support WHO in setting the agenda and content development of the annual WHO HIVResNet meeting.

The Steering Group met virtually on 9 June 2021. Annex 1 provides the meeting agenda and Annex 2 the list of participants. Steering Group members reviewed the activities conducted by the Secretariat in 2020 and provided guidance and direction on activities planned for 2021. Specifically, the Steering Group reviewed and provided technical considerations to the planned content of WHO's 2021 HIV drug resistance report, a proposal to develop a target product profile for HIV drug resistance testing to support individual patient management in low- and middle-income countries, a proposed joint WHO HIVResNet, Clinical Adult working group for Drug Optimization (CADO), and Paediatric working group on Drug Optimization (PADO) meeting and strategic direction on updating the 2017–2021 five-year Global Action Plan on HIV drug resistance.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23491](https://www.yunbaogao.cn/report/index/report?reportId=5_23491)

